– 1. Liu Y, Lai M, Li S, et al. LS‐106, a novel EGFR inhibitor targeting C797S, exhibits anti‐tumor activities both in vitro and in vivo. Cancer Science. 2021
2. Lv S, Pan Q, Lu W, et al.Tenovin 3 induces apoptosis and ferroptosis in EGFR 19del non small cell lung cancer cells.Scientific Reports.2024, 14(1): 7654.
3. Yu J, Zhang L, Peng J, et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochemical pharmacology. 2022, 195: 114864.
4. Shang J, Ning S, Chen Y, et al. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. Acta Pharmacologica Sinica. 2021, 42(1): 120-131
5. Jin Y, Zhang Y, Huang A, et al.Overexpression of SERPINA3 suppresses tumor progression by modulating SPOP/NF‑κB in lung cancer.International Journal of Oncology.2023, 63(2): 1-16.
6. Liang J, Bi G, Sui Q, et al.Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma.Cell Reports.2024, 43(2).
7. Tan J, Zhu L, Shi J, et al.Evaluation of drug resistance for EGFR-TKIs in Lung Cancer via Multicellular lung-on-a-chip.European Journal of Pharmaceutical Sciences.2024: 106805.
8. Zhang Y, Chen Y, Wang B, et al.A novel selenium nanocomposite modified by AANL inhibits tumor growth by upregulating CLK2 in lung cancer.Bioorganic Chemistry.2024: 107459.
9. Wei X, Zhang G, Liu Q, et al.Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.Clinical and Translational Oncology.2024: 1-16.
10. Zhang C, Sun Y X, Yi D C, et al.Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell Reports Medicine.2024